Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study is to provide safety information of hemoporfin during the post-marketing period as
required by China Food and Drug Administration (CFDA) regulations in order to identify any
potential drug related treatment factors in the Chinese population, such as
unknown/unexpected adverse reactions, the incidence of adverse reactions under the routine
drug uses.